Alzheimer's Association Comments on Phase 3 Trial Results for Oral Semaglutide Treatment The Alzheimer's Association expresses disappointment over the Phase 3 trials of oral semaglutide, highlighting the need for continued research in Alzheimer's treatment.

Alzheimer's Association Comments on Phase 3 Trial Results for Oral Semaglutide Treatment #United_States #Chicago #Clinical_Trials #Alzheimer's_Association #Oral_Semaglutide

Oral Semaglutide's Promising Impact on Cardiovascular Health in Type 2 Diabetes Patients A recent study reveals that oral semaglutide significantly reduces cardiovascular risks in type 2 diabetes patients, showcasing a considerable 14% decline in major adverse events.

Oral Semaglutide's Promising Impact on Cardiovascular Health in Type 2 Diabetes Patients #United_States #Chicago #Cardiovascular_Health #Type_2_Diabetes #Oral_Semaglutide